Showing results (1231-1240 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 31, 2003
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytomaKarl Bélanger, David MacDonald, Gregory Cairncross, et al.
Investigational New Drugs|October 31, 2003
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcomaPeter Reichardt, Karin Oechsle, Daniel Pink, et al.
Investigational New Drugs|October 28, 2003
The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellumSeamus O'Reilly, Elizabeth O'Hearn, Robert F Struck, et al.
Investigational New Drugs|October 28, 2003
Phase I studies of weekly administration of cytotoxic agents: implications of a mathematical modelDonna K McClish, John D Roberts
Investigational New Drugs|October 28, 2003
Positron emission tomography (PET): expanding the horizons of oncology drug developmentLisa A Hammond, Louis Denis, Umber Salman, et al.
Investigational New Drugs|October 28, 2003
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinomaBeverly Drucker, Jennifer Bacik, Michelle Ginsberg, et al.
Investigational New Drugs|October 28, 2003
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancerGlenn Liu, Kurt Oettel, Howard Bailey, et al.
Investigational New Drugs|August 5, 2004
Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivativesJuan Antonio Marchal, Houria Boulaiz, Inés Suárez, et al.
Investigational New Drugs|August 5, 2004
Inhibitory effect of polypeptide from Chlamys farreri on UVA-induced apoptosis in human keratinocytesMei Dou, YanTao Han, ZhiWu Han, et al.
Investigational New Drugs|August 5, 2004
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivoJoachim Gullbo, Elin Lindhagen, Saadia Bashir-Hassan, et al.
Pageof 372